Kinarus stops midphase study in hospitalized COVID-19 patients early, adding to long list of failed trials September 30, 2022 1:31 am https://www.fiercebiotech.com/biotech/kinarus-stops-midphase-study-hospitalized-covid-19-patients-early-adding-long-list-failed

Aligos demands jury trial to settle Janssen theft allegations, files fraud counterclaims September 29, 2022 6:30 am https://www.fiercebiotech.com/biotech/algios-demands-jury-trial-settle-janssen-theft-allegations-files-counterclaims-fraud-unfair

Biohaven's Nurtec-less pipeline takes another gut punch, fails ALS trial September 29, 2022 6:05 am https://www.fiercebiotech.com/biotech/biohavens-nurtec-less-pipeline-takes-another-gut-punch-fails-als-trial

Troubled CytoDyn ditches COVID-19 indication, enters tricky NASH landscape with new leader at helm September 29, 2022 5:43 am https://www.fiercebiotech.com/biotech/troubled-cytodyn-ditches-covid-19-indication-enters-tricky-nash-landscape-new-leader-helm

Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful September 29, 2022 4:45 am https://www.fiercebiotech.com/biotech/novo-enters-nlrp3-arena-paying-ventus-70m-nash-program

Galecto links blood cancer prospect to reduced fibrosis in early data drop September 29, 2022 4:13 am https://www.fiercebiotech.com/biotech/galecto-links-blood-cancer-prospect-reduced-fibrosis-early-data-drop

With cash dwindling, Axcella shares look at blinded NASH data September 29, 2022 2:40 am https://www.fiercebiotech.com/biotech/cash-dwindling-axcella-shares-look-blinded-nash-data

Good Idera: Pharma buys rare-disease-focused Aceragen in all-stock deal to keep money flowing September 29, 2022 1:49 am https://www.fiercebiotech.com/biotech/good-idera-pharma-buys-rare-disease-focused-aceragen-all-stock-deal-keep-money-flowing

Eisai and Biogen’s phase 3 Alzheimer’s win puts amyloid back in the driver’s seat, for now September 28, 2022 6:30 am https://www.fiercebiotech.com/biotech/eisai-and-biogens-phase-3-alzheimers-win-puts-amyloid-back-therapeutic-target-drivers-seat

Out of Context: CEO says now not the time to build a 'big independent biotech' September 28, 2022 6:22 am https://www.fiercebiotech.com/biotech/context-ceo-says-its-not-his-job-predict-market-only-prepare-it-biotech-cuts-all-excess-fat